Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

RTTNews | 423 gün önce
Stocktwits
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

The European Commission is expected to announce a final decision in the coming months. FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL).

The positive CHMP opinion is supported by results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates and an acceptable safety profile of odronextamab in adults with R/R FL or R/R DLBCL. The EMA previously granted odronextamab Orphan Designation for both FL and DLBCL. Odronextamab is currently under clinical development and has not been approved by any regulatory authority.

Regeneron continues to evaluate the use of odronextamab as a monotherapy and in combination across earlier lines of therapy in challenging-to-treat lymphomas.

Etiketler: REGN
Stocktwits
read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 389 gün önce
Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews | 570 gün önce
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 1151 gün önce
Bay Street May Open On Weak Note

Bay Street May Open On Weak Note

Canadian shares may open on a weak note Monday morning, tracking lower metal prices and European stocks. However, energy stocks may find support on higher oil prices, and help limit market's downside.
RTTNews | 1s 32 dakika önce
Dollar Extends Losses Amidst Powell's Dovish Surprise

Dollar Extends Losses Amidst Powell's Dovish Surprise

A markedly dovish tone in Fed Chair Jerome Powell's speech at the Jackson Hole symposium on Friday weakened the Dollar, resulting in further losses for the currency during the week ended August 22.
RTTNews | 2s 17 dakika önce
German Ifo Business Confidence Strongest Since 2024

German Ifo Business Confidence Strongest Since 2024

German business sentiment hit the highest level in more than two years in August on expectations that the fiscal stimulus would help to kickstart the economic recovery. The business climate index rose to 89.0 in August from 88.6 in the previous month. This was the highest score since April 2024 and also came in above economists' forecast of 88.6. The German economy's recovery remains weak.
RTTNews | 2s 20 dakika önce
CAC 40 Down Nearly 0.6% In Cautious Trade

CAC 40 Down Nearly 0.6% In Cautious Trade

French stocks remain in negative territory on Monday, with investors mostly making cautious moves, looking for some more clarity on U.S. - EU trade deal, and awaiting crucial inflation data from the region.
RTTNews | 2s 54 dakika önce
Araçlar
Ekonomik takvim
Piyasa saatleri
Faiz oranları
Tatil takvimi
Forex Piyasası
Forex Volatilitesi
Forex Korelasyonu
Forex Haberleri
Forex analizi
COT Verisi
Likidite
Forex Hesaplayıcıları
Forex Isı Haritası
Gösterge ısı haritası
Topluluk
Topluluk
Sistemler
En Popüler Sistemler
Stratejiler
Yarışmalar
Forex Grafikleri
Forex Hassaslığı
Outlook İndikatörü
İncelemeler
Brokerlar
Prop Trading Firmaları
VPS Hizmetleri
Signal Sağlayıcılar
EA Programlama Servisleri
Ortaklık Programları
PAMM Broker Servisleri
İndirim Programı Hizmetleri
Trading Platformları
Uzman Danışmanlar
Kripto Borsaları
Ticaret kursları
Brokerlar
Forex Spreadleri
Forex Broker Fiyatları
Forex Broker Swap’ları
Forex Broker Hacmi
Forex Broker Promosyonları
Basın Bülteni
Platform
Widgetlar
Özellikler
API
RSS
Stock Portfolio
Affiliate Software
Gelişmiş Grafikler
Destek
Sıkça sorulan sorular
Yardım
Bizimle iletişime geç
Hata Bildir!
Hakkında
Blog
© 2025 Myfxbook Ltd. Her hakkı saklıdır.
YÜKSEK RİSK UYARI: Döviz trade’i, tüm yatırımcılar için uygun olmayabilecek yüksek düzeyde risk taşır. Kaldıraç, ek risk ve zarara maruz kalma yaratır. Döviz trade’i yapmaya karar vermeden önce yatırım hedeflerinizi, deneyim seviyenizi ve risk toleransınızı dikkatlice değerlendirin. İlk yatırımınızın bir kısmını veya tamamını kaybedebilirsiniz. Kaybetmeyi göze alamayacağınız parayla yatırım yapmayın. Döviz trade’i ile ilgili riskler konusunda kendinizi eğitin ve herhangi bir sorunuz varsa bağımsız bir finans veya vergi danışmanından tavsiye alın. Her türlü veri ve bilgi 'olduğu gibi' yalnızca bilgilendirme amaçlıdır ve trading amaçları veya tavsiye amaçlı değildir. Geçmiş performans gelecekteki sonuçların göstergesi değildir.